Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
Background Belimumab is the first biological agent approved for the treatment of systemic lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not clear. We conducted this meta-analysis and systematic review to compare the efficacy and safety of belimumab with those o...
Saved in:
| Main Authors: | Han Zhang, Juan Chen, Ying Zhang, Na Zhao, Dongmei Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2207671 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01) -
Severe lupus nephritis with nephrotic syndrome after a treatment of belimumab: one case report
by: Gao Yue-ming, et al.
Published: (2021-01-01) -
Clinical application of belimumab in lupus nephritis
by: Zhou Han, et al.
Published: (2022-10-01) -
RESULTS OF AN OBSERVATIONAL PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF BELIMUMAB (BENLYSTA®) IN SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL CLINICAL PRACTICE
by: E. A. Aseeva, et al.
Published: (2016-03-01) -
Belimumab-driven reductions in retinal microvascular density assessed by optical coherence tomography angiography: insights from systemic lupus erythematosus patients
by: Maierhaba Maitiyaer, et al.
Published: (2025-06-01)